Turn Therapeutics Releases Updated Investor Presentation as Company Pursues Pipeline Advancement

Investor Presentation Released Under Regulation FD

Turn Therapeutics Inc. announced the release of an updated investor presentation on July 28, 2026, according to a disclosure filed with the Securities and Exchange Commission. The presentation was furnished as Exhibit 99.1 to the company's current report filing, which was signed by Bradley Burnam, Chief Executive Officer, on the same date. The update represents the company's effort to provide current information to investors and stakeholders regarding its business operations and strategic direction.

The filing indicates that the investor presentation was released through Regulation FD disclosure procedures. Regulation FD, or Regulation Fair Disclosure, requires companies to disclose material information simultaneously to all investors rather than selectively. By filing the presentation through this mechanism, Turn Therapeutics ensured that all market participants had equal access to the information contained within the updated materials at the same time.

Turn Therapeutics' Corporate Structure and Status

Turn Therapeutics Inc. operates as a Delaware corporation with its principal executive offices located at 250 North Westlake Boulevard in Westlake Village, California. The company holds Commission File Number 001-42875 and maintains an IRS Employer Identification Number of 32-0456090. Its common stock trades on The Nasdaq Stock Market LLC under the ticker symbol TTRX, with each share having a par value of $0.0001.

The company is classified as an emerging growth company under the definitions provided in Rule 405 of the Securities Act of 1933 and Rule 12b-2 of the Securities Exchange Act of 1934. The filing indicates that Turn Therapeutics has not elected to use the extended transition period for complying with new or revised financial accounting standards, meaning the company follows the standard compliance timeline required of all public companies.

Leadership Authorization and Filing Details

Bradley Burnam, who serves as Chief Executive Officer of Turn Therapeutics, authorized the current report filing on July 28, 2026. His signature appears on the document as the authorized representative of the company, fulfilling the requirements of the Securities Exchange Act of 1934. The filing was executed in accordance with the legal obligations that public companies must meet when disclosing material events or information to shareholders and the investing public.

The disclosure document identifies the earliest event reported as July 28, 2026, which corresponds to the date the updated investor presentation was released. This alignment ensures that investors and regulators have clarity regarding the timing of the disclosure and can correlate the announcement with any market activity that may occur on or around that date.

Nature and Scope of the Investor Presentation

The updated investor presentation furnished by Turn Therapeutics serves as a corporate communication tool intended to inform investors about the company's business operations, pipeline status, and strategic objectives. While the current report filing does not disclose specific details contained within the presentation itself, the document was deemed sufficiently important to warrant formal SEC disclosure through the Regulation FD process.

The presentation is designated as interactive data in the regulatory filing system, with supporting materials embedded within the Inline XBRL document format. This ensures that the information is accessible to investors, analysts, and other interested parties through the SEC's EDGAR system, maintaining transparency and equal distribution of corporate information across the investor base.

Securities Trading and Market Information

Turn Therapeutics' common stock is publicly traded on The Nasdaq Stock Market LLC under the ticker symbol TTRX. The company maintains a registered class of securities pursuant to Section 12(b) of the Securities Exchange Act of 1934, which requires adherence to ongoing reporting obligations and corporate governance standards. The par value of each share of common stock is $0.0001.

As a Nasdaq-listed company, Turn Therapeutics is subject to the exchange's listing standards, disclosure requirements, and regulatory oversight. The company's investor presentation, released on July 28, 2026, represents part of its broader investor relations strategy to maintain transparent communication with shareholders and the financial markets community. The immediate share price impact was not clear from available public information.

Legal Status of the Disclosure Filing

The current report filing explicitly states that the information contained in Item 7.01, including the investor presentation furnished as Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, nor shall it be subject to the liabilities associated with that section. This language is standard in Regulation FD disclosures and clarifies the legal status of the furnished materials.

Additionally, the filing specifies that the disclosure is not deemed incorporated by reference in any filing under the Securities Act of 1933 or the Securities Exchange Act of 1934, except as expressly set forth by specific reference in such a filing. This legal clarification ensures that investors and legal professionals understand the precise regulatory framework governing the presentation and its potential use in future corporate disclosures or filings.

Emerging Growth Company Classification and Implications

Turn Therapeutics' designation as an emerging growth company carries specific regulatory implications under federal securities law. Emerging growth companies are permitted certain scaled disclosure requirements and regulatory accommodations designed to reduce compliance burdens for smaller public companies. This status affects how the company reports financial information, executive compensation, and other disclosures to the SEC and public investors.

The company's election not to use the extended transition period for complying with new or revised financial accounting standards means that Turn Therapeutics adopts changes to Generally Accepted Accounting Principles on the same timeline as larger, non-emerging growth companies. This decision reflects the company's approach to financial reporting consistency and compliance with evolving accounting standards.

Contact Information and Corporate Operations

Turn Therapeutics maintains its principal executive offices at 250 North Westlake Boulevard, Westlake Village, California 91362. The company's telephone number, including area code, is listed as (818) 564-4011 in the regulatory filing. These contact details enable investors, analysts, regulators, and other stakeholders to communicate with the company regarding corporate matters.

The disclosure contains no notation of a former name or former address change since the last report, indicating that the company's corporate identity and principal business location have remained stable. This information provides continuity for investors tracking the company's development and regulatory compliance over time.

Forward-Looking Considerations for Investors

The release of an updated investor presentation by Turn Therapeutics provides current corporate information to the market, which may be of interest to current shareholders and prospective investors evaluating the company. The presentation likely addresses key aspects of the company's business strategy, clinical pipeline, financial position, and growth prospects, though the specific contents are not detailed in the regulatory filing itself.

Investors and analysts may wish to review the complete investor presentation through the SEC's EDGAR system to obtain detailed information about Turn Therapeutics' operations and strategic initiatives. The presentation represents management's current view of the company's business and market positioning, and may provide insights into the company's approach to development and commercialization activities.